Spravato
(Esketamine)ApprovedSmall molecule
Esketamine is used to treat severe depression, particularly in people who haven't responded well to other antidepressants, and to reduce suicidal thoughts in people in crisis.[2] Spravato is currently approved and in use across 36 indications[4].[1]
Spravato is one of 707 small molecule programs targeting Fatigue. It is currently in Approved.
36
Indications
143
Total Trials
43
Active Trials
706
Competitors
1
FDA Application
NDA/BLA/ANDA regulatory filings
7
Patents
Pipeline
Status by Indication[4][1]
Indication
Showing 10 of 33 indications
Competition
Competitive Landscape
2828 competitors in Breast Cancer
#DrugCompanyPhaseTrials
1Spravato
WWim Janssens
Approved
Prolia
AmgenPreclinical
DATROWAY
Daiichi SankyoPreclinical
Megace
Bristol-Myers SquibbPreclinical
Lupron
EEastern Cooperative Oncology Group
Preclinical
Tricor
JJagotec
Preclinical
QS21
MMemorial Sloan Kettering Cancer Center
Preclinical
Apatinib Mesylate
BBukwang Pharmaceutical
Preclinical
Tianeptine
PfizerPreclinical
Recombinant Human Chorionic Gonadotropin
Merck & Co.Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Esketamine26 trials
ED50 of Esketamine for Laser Treatment in Children
Unknown status·—·N/A·NCT06294639·40 enrolled
Show 23 more trials
Fentanyl or Esketamine for Traumatic PAIN (FORE-PAIN) Trial
Recruiting·—·Phase 3·NCT06051227·608 enrolled
Intranasal Esketamine and Fentanyl for Pain in Minor Trauma
Unknown status·—·Phase 4·NCT03421275·105 enrolled
Esketamine and Butorphanol for Post-Lobectomy Pain
Completed·—·Phase 4·NCT06398834·223 enrolled
Effect of Esketamine on Conscious State in Patients With pDoC
Recruiting·—·N/A·NCT06389344·116 enrolled
Treatment Resistant Depression16 trials
Show 13 more trials
Major Depressive Disorder9 trials
Show 6 more trials
Intensified Pharmacological Treatment for Schizophrenia, Major Depressive Disorder and Bipolar Depression After a First-time Treatment Failure
Recruiting·—·Phase 3·NCT05603104·1,254 enrolled
Sedation5 trials
Show 2 more trials
Depression5 trials
Personalized DBS Targeting for Treating Depression
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06784388·5 enrolled
65 more indications
Anxiety4 trials
Dexmedetomidine4 trials
Delirium4 trials
Hepatocellular Carcinoma2 trials
Effect of Esketamine on Abdominal Pain During TACE-HAIC in Patients With Hepatocellular Carcinoma
Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 4·NCT05416073·70 enrolled
Effects of Esketamine on Acute Abdominal Pain After TACE in Patients With Hepatocellular Carcinoma
Unknown status·TThe Second Affiliated Hospital of Chongqing Medical University·Phase 4·NCT05670561·60 enrolled
Hemodynamic Stability2 trials
Breast Cancer2 trials
Thoracoscopic Surgery2 trials
Postpartum Depression2 trials
Post Operative Pain2 trials
Septic Shock2 trials
Suicide2 trials
Autism Spectrum Disorder1 trial
Effectiveness1 trial
The Effectiveness and Safety of Esketamine in Modified Electroconvulsive Therapy
Unknown status·FFirst Affiliated Hospital of Chongqing Medical University·Phase 1·NCT04777110·396 enrolled
Renal Impairment1 trial
Depressive Symptoms1 trial
Esketamine and Perioperative Depressive Symptoms
Completed·—·Phase 2/3·NCT04425473·435 enrolled
Acute Pain1 trial
ESKetamine Low-dose vs Ketamine Low-dose for Severe Acute Pain in Emergency Units, Comparison of PsychodyslEptic Effects
Recruiting·—·Phase 4·NCT06853041·74 enrolled
Cardiac Surgery1 trial
Suicidality1 trial
Esketamine vs ECT for Acute Suicidality
Completed·—·N/A·NCT06355180·340 enrolled
Postoperative Pain Relief1 trial
Bariatric Surgery1 trial
Hysterectomy1 trial
Gastrointestinal Function1 trial
Pain After Surgery1 trial
Valve Surgery1 trial
Effect of Esketamine on Perioperative Negative Mood in Patients Undergoing Cardiac Valve Surgery
Completed·—·N/A·NCT06608030·142 enrolled
Treatment Resistant Depression (TRD)1 trial
Parkinson's Disease1 trial
Esketamine in Microelectrode Recording-guided Subthalamic Deep-Brain Stimulation for Parkinson's Disease
Recruiting·—·N/A·NCT06543563·102 enrolled
Painless Gastrointestinal Endoscopy1 trial
Effect of Low-dose Esketamine Combined With Target-controlled Infusion of Propofol for Painless Gastrointestinal Endoscopy
Unknown status·—·N/A·NCT04691076·1,000 enrolled
Ovarian Cancer1 trial
Postoperative Sleep Disturbance1 trial
Esketamine on Postoperative Sleep Disturbance of Patients Undergoing Spinal Surgery
Recruiting·—·N/A·NCT06451627·156 enrolled
Postherpetic Neuralgia1 trial
The Study on the Esketamine in the Treatment of Postherpetic Neuralgia
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04664530·48 enrolled
Hepatic Impairment1 trial
Cognitive Function1 trial
Quadratus Lumborum Block1 trial
Thoracic Paravertebral Block1 trial
Irritable Bowel Syndrome1 trial
Efficacy of Esketamine for Patients With Irritable Bowel Syndrome
Recruiting·—·N/A·NCT06788444·552 enrolled
Anesthesia1 trial
Effects of Esketamine on Recovery of Consciousness After Propofol Anesthesia
Recruiting·—·N/A·NCT06430645·150 enrolled
Cesarean Section1 trial
Scoliosis1 trial
Obesity1 trial
Critically Ill Patients1 trial
Postoperative Recovery1 trial
Inflammatory Bowel Disease1 trial
Allergic Rhinitis1 trial
Intraoperative1 trial
Intraoperative Small-dose Esketamine Infusion for Pain Control in Burn Patients
Unknown status·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 4·NCT04682782·26 enrolled
Postoperative Quality of Recovery1 trial
Spinal Cord Injury1 trial
Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury
Not yet recruiting·—·N/A·NCT06531837·60 enrolled
Abuse Potential1 trial
Cardiac Repolarization1 trial
Post-Traumatic Stress Disorder1 trial
Combining Esketamine and Prolonged Exposure Treatment for PTSD (Post Traumatic Stress Disorder)
Completed·TThe University of Texas Health Science Center at San Antonio·Phase 1/2·NCT06795659·4 enrolled
Efficacy and Safety1 trial
Attention1 trial
Depth of Anesthesia1 trial
Laparoscopic Cholecystectomy1 trial
Old Age1 trial
Depressive Disorder, Major1 trial
Regulatory
FDA Approval Timeline[5]
Mar 5, 2019
SPRAVATO
NDA NDA211243
Sources
References
- [1]
- [2]MedlinePlus Drug Information — Spravato drug information. U.S. National Library of Medicine, National Institutes of Health.
- [3]
- [4]Open Targets Platform — Drug–disease associations for Esketamine. EMBL-EBI & Wellcome Sanger Institute.
- [5]
- [6]
- [7]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Glutamate [NMDA] Receptor Negative Allosteric Modulator[3]
- Modality
- Small molecule[3]
- Highest Phase
- Approved[1]
- Company
- WWim Janssens